May 26, 2024
Cardiac Valvulotome Market

Cardiac Valvulotome Market Trends in Minimally Invasive Procedures

Cardiac valvulotomes are used to cut or dilate stenotic heart valves during valve replacement surgeries. They facilitate minimally invasive procedures by allowing surgeons to access the heart valves through small incisions instead of open-heart surgeries. This reduces postoperative pain, recovery time, and risk of complications for patients. Growing prevalence of valvular heart diseases worldwide due to rising geriatric population is a major driver for the market.

The global cardiac valvulotome market is estimated to be valued at US$ 157.2 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Cardiac Valvulotome Market Demand are LeMaitre, INVAMED, GeoSurgical, LimFlow, Inc., B. Braun SE, Teleflex Incorporated, StarFish Product Engineering Inc., Koven Technology Canada Inc., Andramed, Zgrum Medical, BD, PEAK SURGICAL, and Symmetry Surgical Inc. These companies offer a variety of valvulotomes that can be used for both mechanical and incisionless procedures.

The growing demand for minimally invasive cardiac surgeries is fueling market growth. Advantages such as lesser pain, faster recovery, and lower morbidity have increased adoption of techniques like transcatheter aortic valve replacement which utilize valvulotomes.

Globally, rising incidences of rheumatic heart disease and age-related valvular issues are seen. This is prompting healthcare providers as well as players in developed markets to expand in emerging regions to meet the growing need. Partnerships with surgical centers and hospitals in Asia Pacific and Latin America have increased in recent years.

Market Key Trends

The trend of using catheters, guidewires and other tools for incisionless valvuloplasty procedures instead of open-heart surgeries is driving innovations in cardiac valvulotome designs. Manufacturers are developing low profile, flexible valvulotomes that can be delivered percutaneously. This enables treatments for high-risk patients and expands the pool of treatable valvular disorders. Such minimally invasive valvular interventions without cardiopulmonary bypass continue to gain popularity.

Porter’s Analysis

Threat of new entrants: The cardiac valvulotome market requires high investments for R&D and to gain regulatory approvals, this poses as a barrier for new players.

Bargaining power of buyers: Buyers have moderate bargaining power given the availability of alternative valvulotome products from different manufacturers.

Bargaining power of suppliers: A small number of suppliers provide raw materials for valvulotomes, giving them higher bargaining power.

Threat of new substitutes: Alternatives like valvuloplasty balloons and transcatheter heart valves pose a threat, however valvulotomes still have usage in certain procedures.

Competitive rivalry: Being a moderately consolidated market, companies compete on the basis of product innovations, quality, and geographic expansion.

Geographical regions: North America is currently dominating the market due to a high prevalence of valvular diseases and a large number of surgeries.

The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to growing healthcare infrastructure, rising medical tourism, and increasing cases of heart diseases.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it